Pembrolizumab in Combination With Axitinib as First-Line Treatment for Patients With RCC: Evidence to Date
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Pembrolizumab in Combination With Axitinib as First-Line Treatment for Patients With Renal Cell Carcinoma (RCC): Evidence to Date
Cancer Manag Res 2020 Sep 01;12(2020)7321-7330, V Chau, M BilusicFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.